-
HE4 is a biomarker for ovarian cancer (systematic review and meta-analysis)
-
These results may be commented as HE4 expression rises in patients with HER2/neu amplification.
-
Serum HE4 with its high specificity is useful in ruling out ovarian malignancy especially among the premenopausal women and Risk of Ovarian Malignancy Algorithm (ROMA)which is the combination of both serum CA 125 and HE4, appears to be an all-rounder with overall good sensitivity and specificity especially among the postmenopausal women.
-
CA125 appears the most reliable biomarker for OC monitoring, whereas HE4 contributes additional information only in a minority of cases
-
level of HE4 might predict chemoresistance and the possibility of ascites formation. The determination of the expression of HE4 alone or combined with CA125 levels in both serum and ascites in ovarian cancer patients with ascites may have important significance for guiding and improving the treatment
-
Elevated serum HE4 in SLE patients is significantly associated with a higher risk of incidence for lupus nephritis (LN), and may be a useful predictor for developing LN.
-
HE4 has the potential to be used as a novel clinical biomarker for evaluating kidney function and predicting renal fibrosis in kidney transplant recipients
-
A panel of three tumor markers CYFRA 21.1, HE4 and ProGRP may play a role for discriminating LC from benign lung disease and subtyping as SCLC.
-
Serum Smac expression level was significantly lower in the EAOC group than in the control group and benign ovarian tumor group (P< 0.05), while HE4 and CA125 expression levels were significantly higher in the EAOC group than the other two groups.
-
This study demonstrated that altered expression of HE4 may involve in tumorigenesis in the uterine cervix. Our findings also suggested the presence of a correlation between HE4 expression and the invasive potential of uterine tumors. Therefore it may be thought that the tissue expression of HE4 can be used to differentiate high grade intraepithelial tumors from carcinomas.
-
High serum HE4 level is associated with epithelial ovarian cancer.
-
Use of HE4 instead of CA125 did not significantly improve diagnostic performance of risk of malignancy indices 1-4 in patients with an adnexal mass
-
The significant effect of the normalization of the HE4 marker after therapy and 50% reduction of HE4 levels before interval cytoreductive surgery on PFS and OS confirmed that HE4 might be an independent prognostic factor of treatment response.
-
HE4 could help with the differentiation of prognostically varied patient groups as well as with the decision-making process associated with the development of individual treatment plans
-
Studied serum levels of Parkinson's disease-associated protein 7 (DJ-1) and human epididymis protein 4 (HE4) in endometrial cancer (EC) patients and healthy controls. The median serum concentrations of DJ-1 and HE4 were found to be significantly higher in EC patients compared to controls.
-
HE4 is a biomarker for ovarian cancer recurrence [review]
-
Numerous studies indicated that HE4 is able to promote cancer progression and drug resistance. These observations strongly suggest that HE4 may play a significant role in cancer recurrence through its bioactivity in the regulation of malignant behavior at the cellular level. Overall, available data shows that high serum HE4 levels correlate well with ovarian cancer recurrence. [review]
-
WFCD2, which is up-regulated in ovarian cancer, can now for the first time be considered a regulator of tumor metastasis.
-
High HE4 expression is associated with adnexal malignancy.
-
Architect CA 125 II and HE4 values in Chinese women presenting with a pelvic mass
